MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
August 2, 2019
9:00 A.M.
Conference Center Room “A”
Indiana State Government Center South

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of May 3, 2019
4. Preferred Drug List: Therapeutic Class Re-Review
   a) Respiratory
      i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
      ii. Antiviral Monoclonal Antibodies
      iii. Beta Adrenergics and Corticosteroids
      iv. Beta Agonists
      v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
      vi. Leukotriene Receptor Antagonists
      vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
      viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
      ix. Oral Inhaled Glucocorticoids
      x. Phosphodiesterase-4 Inhibitors
xi. Pulmonary Antihypertensives

b) Anti-Infectives
   i. Antivirals – Anti-Herpetic Agents
   ii. Antivirals – Influenza Agents
   iii. Cephalosporins – 3rd Generation
   iv. Fluoroquinolones
   v. Hepatitis C Agents
   vi. Macrolides
   vii. Ophthalmic Antibiotics
   viii. Ophthalmic Antibiotics/Corticosteroid Combinations
   ix. Oral Non-Systemic Antifungals
   x. Otic Antibiotics
   xi. Systemic Antifungals
   xii. Topical Antifungals
   xiii. Topical Antivirals
   xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
   xv. Vaginal Antimicrobials
c) Cardiovascular
   i. Angiotensin-Converting Enzyme (ACE) Inhibitors
   ii. ACE Inhibitor Combinations
   iii. Alpha Adrenergic Blockers
   iv. Angiotensin II Receptor Antagonists (ARBs)
   v. ARB Combinations
   vi. Beta Adrenergic Blockers
   vii. Beta Adrenergic Blockers with Diuretics
   viii. Calcium Channel Blockers (CCBs)
   ix. CCBs with HMG-CoA Reductase Inhibitors
   x. Miscellaneous Cardiac Agents
d) Lipotropics
   i. Bile Acid Sequestrants
   ii. Fibric Acid Derivatives
iii. HMG-CoA Reductase Inhibitors
iv. Lipotropics
e) Antimigraine Agents
f) Electrolyte Depleters
g) Multiple Sclerosis Agents

5. New Business

6. Public Comment

7. Other Business

8. Adjourn